Diapositive 1
|
02 Pruschy How do we target- final |
1 |
|
03 Personalized Medicine 14.06.2017 |
58 |
|
04 ESTRO Breast 15.06.2017 |
124 |
|
05 Immunotherapeutics GC 01.05.2017 |
168 |
|
06 Hennequin esophageal cancer |
219 |
|
06b Oeso2 |
296 |
|
07 Rationale ART and CRT 2017_Brussels |
316 |
|
08 Tumor Hypoxia Point of View Biologist Pruschy |
377 |
|
08b Hypoxia_ RO view 2017_Brussels |
434 |
|
09 Tan Cervix Brussels 2017 |
477 |
|
10 Immuno-radiotherapy 2017_Brussels |
541 |
|
13 Tan Decision making |
578-579 |
|
14 ESTRO Bruxelles June 2017 - anal Glynne-Jones |
740 |
|
15 Brain - Levis |
828 |
|
16 Pruschy- Biology Friday late afternoon |
917 |
|
17 NSCLC - Levis |
948 |
|
18 SCLC - Levis |
1061 |
|
19 Pruschy Point of View Biologist |
1124 |
|
20-21 CRT_Head and Neck 2017_Brussels |
1156 |
|
21b Head and Neck case 2015 |
1253 |
|
21c Head and Neck case 2017 |
1281 |
|
23 ESTRO Bruxelles 2017 chemorad endpoints - outcomes final_TP |
1308 |
|
24 Lymphoma - Levis |
1384 |
|
26 Tan Gynae Brussels 2017 |
1509 |
|
27 ESTRO Rectal chemoradiation Bruxelles 2017 Glynne Jones rejigged_TP |
1612 |
|
27b ESTRO Rectal chemoradiation Bruxelles 2017 Glynne Jones_TP |
1707 |
|
28 pres-Jereczek-NEW-DRUGS |
1801 |